Figure 1
From: NTG-101: A Novel Molecular Therapy that Halts the Progression of Degenerative Disc Disease
Pro-anabolic effects of combination treatment on human NP cells. (a) Panel shows histograms representing average cell viability (%) of human NP cells (H1- H8) treated with the combination of rhCTGF and rhTGF-β1 proteins for 48 hrs and 72 hrs in comparison to No treatment controls (NTC, shown by single bar as a representative for % cell viability 48 hrs and 72 hrs) as determined using cell viability assays (*p ≤ 0.05, **p < 0.005). (b) Panel shows histograms representing average cell proliferation (%) of human NP cells (H1 - H8) treated with the combination of rhCTGF and rhTGF-β1 proteins for 72 hrs as compared to No treatment controls (NTC) determined using BrdU enzyme linked immunosorbent assay (ELISA) assay (*p ≤ 0.05). Total RNA was extracted human NP cells (H1- H8) treated with combination treatment or left untreated in growth medium for 24 hrs to determine the effect of treatment on expression of healthy ECM genes. qRT-PCR analysis showing mRNA expression levels of (c) aggrecan, (d) Col2A1 and (e) HAPLN1 in human NP cells (H1- H8) treated with the combination of rhCTGF and rhTGF-β1 proteins for 24 hrs in comparison to their respective No treatment controls (NTC, *p ≤ 0.05).
